Antiviral effects of artesunate on JC polyomavirus replication in COS-7 Cells

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 11, 2014, Pages 6724-6734

  Sharma, Biswa Nath ^a,b   Marschall, Manfred ^c   Rinaldo, Christine Hanssen ^a,b  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTESUNATE; CELL DNA; PROTEIN VP1; ANTIVIRUS AGENT; ARTEMISININ DERIVATIVE; VIRUS DNA;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; COS 7 CELL LINE; CYTOTOXICITY; EC50; HEK293 CELL LINE; IN VITRO STUDY; JC VIRUS; NONHUMAN; PROTEIN EXPRESSION; SIMIAN VIRUS 40; VIRUS REPLICATION; VIRUS STRAIN; ANIMAL; CELL LINE; CELL SURVIVAL; CHLOROCEBUS AETHIOPS; COS 1 CELL LINE; DRUG EFFECTS; HUMAN; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; METABOLISM; MICROBIAL SENSITIVITY TEST; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; ARTEMISININS; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CERCOPITHECUS AETHIOPS; COS CELLS; DNA, VIRAL; HEK293 CELLS; HUMANS; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MICROBIAL SENSITIVITY TESTS; VIRUS REPLICATION;

EID: 84908563197     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03714-14     Document Type: Article

References (66)

1. Padgett BL, Walker DL, ZuRhein GM, Eckroade RJ, Dessel BH. 1971. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet i:1257-1260.
2. Ferenczy MW, Marshall LJ, Nelson CD, Atwood WJ, Nath A, Khalili K, Major EO. 2012. Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin. Microbiol. Rev. 25:471-506. http://dx.doi.org/10.1128/CMR.05031-11.
3. Hirsch HH, Kardas P, Kranz D, Leboeuf C. 2013. The human JC polyomavirus (JCPyV): virological background and clinical implications. APMIS 121:685-727. http://dx.doi.org/10.1111/apm.12128.
4. Alstadhaug KB, Croughs T, Henriksen S, Leboeuf C, Sereti I, Hirsch HH, Rinaldo CH. 2014. Treatment of progressive multifocal leukoencephalopathy with interleukin JAMA Neurol. 71:1030-1035. http://dx.doi.org/10.1001/jamaneurol.2014.825.
5. Gheuens S, Wüthrich C, Koralnik IJ. 2013. Progressive multifocal leukoencephalopathy: why gray and white matter. Annu. Rev. Pathol. 8:189-215. http://dx.doi.org/10.1146/annurev-pathol-020712-164018.
6. Naess H, Glad S, Storstein A, Rinaldo CH, Mørk SJ, Myhr KM, Hirsch H. 2010. Progressive multifocal leucoencephalopathy in an immunocompetent patient with favourable outcome. A case report. BMC Neurol. 10 http://dx.doi.org/10.1186/1471-2377-10-32
7. Gheuens S, Pierone G, Peeters P, Koralnik IJ. 2010. Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression. J. Neurol. Neurosurg. Psychiatry 81:247-254. http://dx.doi.org/10.1136/jnnp.2009.187666.
8. Egli A, Infanti L, Dumoulin A, Buser A, Samaridis J, Stebler C, Gosert R, Hirsch HH. 2009. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J. Infect. Dis. 199:837-846. http://dx.doi.org/10.1086/597126.
9. Knowles WA, Pipkin P, Andrews N, Vyse A, Minor P, Brown DW, Miller E. 2003. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J. Med. Virol. 71:115-123. http://dx.doi.org/10.1002/jmv.10450.
10. Stolt A, Sasnauskas K, Koskela P, Lehtinen M, Dillner J. 2003. Seroepidemiology of the human polyomaviruses. J. Gen. Virol. 84:1499-1504. http://dx.doi.org/10.1099/vir.0.18842-0.
11. Chesters PM, Heritage J, McCance DJ. 1983. Persistence of DNA sequences of BK virus and JC virus in normal human tissues and in diseased tissues. J. Infect. Dis. 147:676-684. http://dx.doi.org/10.1093/infdis/147 .4.676.
12. Monaco MC, Atwood WJ, Gravell M, Tornatore CS, Major EO. 1996. JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency. J. Virol. 70:7004-7012.
13. White FA, III, Ishaq M, Stoner GL, Frisque RJ. 1992. JC virus DNA is present in many human brain samples from patients without progressive multifocal leukoencephalopathy. J. Virol. 66:5726-5734.
14. Bayliss J, Karasoulos T, McLean CA. 2012. Frequency and large T (LT) sequence of JC polyomavirus DNA in oligodendrocytes, astrocytes and granular cells in non-PML brain. Brain Pathol. 22:329-336. http://dx.doi.org/10.1111/j.1750-3639.2011.00538.x.
15. Johne R, Buck CB, Allander T, Atwood WJ, Garcea RL, Imperiale MJ, Major EO, Ramqvist T, Norkin LC. 2011. Taxonomical developments in the family Polyomaviridae. Arch. Virol. 156:1627-1634. http://dx.doi.org/10.1007/s00705-011-1008-x.
16. Trowbridge PW, Frisque RJ. 1995. Identification of three new JC virus proteins generated by alternative splicing of the early viral mRNA. J. Neurovirol. 1:195-206. http://dx.doi.org/10.3109/13550289509113966.
17. Gosert R, Kardas P, Major EO, Hirsch HH. 2010. Rearranged JC virus noncoding control regions found in progressive multifocal leukoencephalopathy patient samples increase virus early gene expression and replication rate. J. Virol. 84:10448-10456. http://dx.doi.org/10.1128/JVI.00614-10.
18. Padgett BL, Rogers CM, Walker DL. 1977. JC virus, a human polyomavirus associated with progressive multifocal leukoencephalopathy: additional biological characteristics and antigenic relationships. Infect. Immun. 15:656-662.
19. Gosert R, Rinaldo CH, Wernli M, Major EO, Hirsch HH. 2011. CMX001 (1-O-hexadecyloxypropyl-cidofovir) inhibits polyomavirus JC replication in human brain progenitor-derived astrocytes. Antimicrob. Agents Chemother. 55:2129-2136. http://dx.doi.org/10.1128/AAC.00046-11.
20. Gluzman Y. 1981. SV40-transformed simian cells support the replication of early SV40 mutants. Cell 23:175-182. http://dx.doi.org/10.1016/0092-8674(81)90282-8.
21. Hara K, Sugimoto C, Kitamura T, Aoki N, Taguchi F, Yogo Y. 1998. Archetype JC virus efficiently replicates in COS-7 cells, simian cells constitutively expressing simian virus 40 T antigen. J. Virol. 72:5335-5342.
22. Buck CB, Pastrana DV, Lowy DR, Schiller JT. 2004. Efficient intracellular assembly of papillomaviral vectors. J. Virol. 78:751-757. http://dx.doi.org/10.1128/JVI.78.2.751-757.2004.
23. Broekema NM, Imperiale MJ. 2012. Efficient propagation of archetype BK and JC polyomaviruses. Virology 422:235-241. http://dx.doi.org/10.1016/j.virol.2011.10.026.
24. Shaw G, Morse S, Ararat M, Graham FL. 2002. Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells. FASEB J. 16:869-871. http://dx.doi.org/10.1096/fj.01-0995fje.
25. Major EO, Miller AE, Mourrain P, Traub RG, de Widt E, Sever J. 1985. Establishment of a line of human fetal glial cells that supports JC virus multiplication. Proc. Natl. Acad. Sci. U. S. A. 82:1257-1261. http://dx.doi.org/10.1073/pnas.82.4.1257.
26. Henriksen S, Tylden GD, Dumoulin A, Sharma BN, Hirsch HH, Rinaldo CH. 2014. The human fetal glial cell line SVG p12 contains infectious BK polyomavirus (BKPyV). J. Virol. 88:7556-7568. http://dx.doi.org/10.1128/JVI.00696-14.
27. Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, Chhaganlal KD, Bojang K, Olaosebikan R, Anunobi N, Maitland K, Kivaya E, Agbenyega T, Nguah SB, Evans J, Gesase S, Kahabuka C, Mtove G, Nadjm B, Deen J, Mwanga-Amumpaire J, Nansumba M, Karema C, Umulisa N, Uwimana A, Mokuolu OA, Adedoyin OT, Johnson WB, Tshefu AK, Onyamboko MA, Sakulthaew T, Ngum WP, Silamut K, Stepniewska K, Woodrow CJ, Bethell D, Wills B, Oneko M, Peto TE, von Seidlein L, Day NP, White NJ, AQUAMAT Group. 2010. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 376: 1647-1657. http://dx.doi.org/10.1016/S0140-6736(10)61924-1.
28. Romero MR, Efferth T, Serrano MA, Castano B, Macias RI, Briz O, Marin JJ. 2005. Effect of artemisinin/artesunate as inhibitors of hepatitis B virus production in an "in vitro" replicative system. Antiviral Res. 68:75- 83 http://dx.doi.org/10.1016/j.antiviral.2005.07.005
29. Auerochs S, Korn K, Marschall M. 2011. A reporter system for Epstein-Barr virus (EBV) lytic replication: anti-EBV activity of the broad antiherpesviral drug artesunate. J. Virol. Methods 173:334-339. http://dx.doi.org/10.1016/j.jviromet.2011.03.005.
30. Romero MR, Serrano MA, Vallejo M, Efferth T, Alvarez M, Marin JJ. 2006. Antiviral effect of artemisinin from Artemisia annua against a model member of the Flaviviridae family, the bovine viral diarrhoea virus (BVDV). Planta Med. 72:1169-1174. http://dx.doi.org/10.1055/s-2006-947198.
31. Milbradt J, Auerochs S, Korn K, Marschall M. 2009. Sensitivity of human herpesvirus 6 and other human herpesviruses to the broadspectrum antiinfective drug artesunate. J. Clin. Virol. 46:24-28. http://dx.doi.org/10.1016/j.jcv.2009.05.017.
32. Efferth T, Romero MR, Wolf DG, Stamminger T, Marin JJ, Marschall M. 2008. The antiviral activities of artemisinin and artesunate. Clin. Infect. Dis. 47:804-811. http://dx.doi.org/10.1086/591195.
33. Efferth T, Marschall M, Wang X, Huong SM, Hauber I, Olbrich A, Kronschnabl M, Stamminger T, Huang ES. 2002. Antiviral activity of artesunate towards wild-type, recombinant, and ganciclovir-resistant human cytomegaloviruses. J. Mol. Med. (Berl.) 80:233-242. http://dx.doi.org/10.1007/s00109-001-0300-8.
34. Shapira MY, Resnick IB, Chou S, Neumann AU, Lurain NS, Stamminger T, Caplan O, Saleh N, Efferth T, Marschall M, Wolf DG. 2008. Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin. Infect. Dis. 46:1455-1457. http://dx.doi.org/10.1086/587106.
35. Germi R, Mariette C, Alain S, Lupo J, Thiebaut A, Brion JP, Epaulard O, Saint Raymond C, Malvezzi P, Morand P. 2014. Success and failure of artesunate treatment in five transplant recipients with disease caused by drug-resistant cytomegalovirus. Antiviral Res. 101:57-61. http://dx.doi.org/10.1016/j.antiviral.2013.10.014.
36. Hakacova N, Klingel K, Kandolf R, Engdahl E, Fogdell-Hahn A, Higgins T. 2013. First therapeutic use of artesunate in treatment of human herpesvirus 6B myocarditis in a child. J. Clin. Virol. 57:157-160. http://dx.doi.org/10.1016/j.jcv.2013.02.005.
37. Wolf DG, Shimoni A, Resnick IB, Stamminger T, Neumann AU, Chou S, Efferth T, Caplan O, Rose J, Nagler A, Marschall M. 2011. Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation. Antiviral Res. 90:183-186. http://dx.doi.org/10.1016/j.antiviral.2011.03.184.
38. Lau PK, Woods ML, Ratanjee SK, John GT. 2011. Artesunate is ineffective in controlling valganciclovir-resistant cytomegalovirus infection. Clin. Infect. Dis. 52:279. http://dx.doi.org/10.1093/cid/ciq050.
39. Sharma BN, Marschall M, Henriksen S, Rinaldo CH. 2014. Antiviral effects of artesunate on polyomavirus BK replication in primary human kidney cells. Antimicrob. Agents Chemother. 58:279-289. http://dx.doi.org/10.1128/AAC.01800-13.
40. McLaurin J, Trudel GC, Shaw IT, Antel JP, Cashman NR. 1995. A human glial hybrid cell line differentially expressing genes subserving oligodendrocyte and astrocyte phenotype. J. Neurobiol. 26:283-293. http://dx.doi.org/10.1002/neu.480260212.
41. Padgett BL, Walker DL, ZuRhein GM, Hodach AE, Chou SM. 1976. JC papovavirus in progressive multifocal leukoencephalopathy. J. Infect. Dis. 133:686-690. http://dx.doi.org/10.1093/infdis/133.6.686.
42. Schweighardt B, Shieh JT, Atwood WJ. 2001. CD4/CXCR4-independent infection of human astrocytes by a T-tropic strain of HIV-1. J. Neurovirol. 7:155-162. http://dx.doi.org/10.1080/13550280152058816.
43. Drachenberg CB, Hirsch HH, Papadimitriou JC, Gosert R, Wali RK, Munivenkatappa R, Nogueira J, Cangro CB, Haririan A, Mendley S, Ramos E. 2007. Polyomavirus BK versus JC replication and nephropathy in renal transplant recipients: a prospective evaluation. Transplantation 84:323-330. http://dx.doi.org/10.1097/01.tp.0000269706.59977.a5.
44. Hey AW, Johnsen JI, Johansen B, Traavik T. 1994. A two fusion partner system for raising antibodies against small immunogens expressed in bacteria. J. Immunol. Methods 173:149-156. http://dx.doi.org/10.1016/0022-1759(94)90294-1.
45. Rinaldo CH, Gosert R, Bernhoff E, Finstad S, Hirsch HH. 2010. 1-OHexadecyloxypropyl cidofovir (CMX001) effectively inhibits polyomavirus BK replication in primary human renal tubular epithelial cells. Antimicrob. Agents Chemother. 54:4714-4722. http://dx.doi.org/10.1128/AAC.00974-10.
46. Sharma BN, Li R, Bernhoff E, Gutteberg TJ, Rinaldo CH. 2011. Fluoroquinolones inhibit human polyomavirus BK (BKV) replication in primary human kidney cells. Antiviral Res. 92:115-123. http://dx.doi.org/10.1016/j.antiviral.2011.07.012.
47. Schowalter RM, Buck CB. 2013. The Merkel cell polyomavirus minor capsid protein. PLoS Pathog. 9:e1003558. http://dx.doi.org/10.1371/journal.ppat.1003558.
48. Mázló M, Tariska I. 1982. Are astrocytes infected in progressive multifocal leukoencephalopathy (PML)? Acta Neuropathol. 56:45-51. http://dx.doi.org/10.1007/BF00691181.
49. Lööv C, Hillered L, Ebendal T, Erlandsson A. 2012. Engulfing astrocytes protect neurons from contact-induced apoptosis following injury. PLoS One 7:e33090. http://dx.doi.org/10.1371/journal.pone.0033090.
50. Chou S, Marousek G, Auerochs S, Stamminger T, Milbradt J, Marschall M. 2011. The unique antiviral activity of artesunate is broadly effective against human cytomegaloviruses including therapy-resistant mutants. Antiviral Res. 92:364-368. http://dx.doi.org/10.1016/j.antiviral.2011.07 .018.
51. Efferth T, Kaina B. 2010. Toxicity of the antimalarial artemisinin and its dervatives. Crit. Rev. Toxicol. 40:405-421. http://dx.doi.org/10.3109/10408441003610571.
52. Flobinus A, Taudon N, Desbordes M, Labrosse B, Simon F, Mazeron MC, Schnepf N. 2014. Stability and antiviral activity against human cytomegalovirus of artemisinin derivatives. J. Antimicrob. Chemother. 69: 34-40. http://dx.doi.org/10.1093/jac/dkt346.
53. Lynch KJ, Frisque RJ. 1990. Identification of critical elements within the JC virus DNA replication origin. J. Virol. 64:5812-5822.
54. Jiang Z, Chai J, Chuang HH, Li S, Wang T, Cheng Y, Chen W, Zhou D. 2012. Artesunate induces G0/G1 cell cycle arrest and iron-mediated mitochondrial apoptosis in A431 human epidermoid carcinoma cells. Anticancer Drugs 23:606-613. http://dx.doi.org/10.1097/CAD .0b013e328350e8ac.
55. Li S, Xue F, Cheng Z, Yang X, Wang S, Geng F, Pan L. 2009. Effect of artesunate on inhibiting proliferation and inducing apoptosis of SP2/0 myeloma cells through affecting NFkappaB p65. Int. J. Hematol. 90:513-521. http://dx.doi.org/10.1007/s12185-009-0409-z.
56. Xu Q, Li ZX, Peng HQ, Sun ZW, Cheng RL, Ye ZM, Li WX. 2011. Artesunate inhibits growth and induces apoptosis in human osteosarcoma HOS cell line in vitro and in vivo. J. Zhejiang Univ. Sci. B 12:247-255. http://dx.doi.org/10.1631/jzus.B1000373.
57. Sullivan CS, Pipas JM. 2002. T antigens of simian virus 40: molecular chaperones for viral replication and tumorigenesis. Microbiol. Mol. Biol. Rev. 66:179-202. http://dx.doi.org/10.1128/MMBR.66.2.179-202.2002.
58. Heredero-Bermejo I, Copa-Patino JL, Soliveri J, Gómez R, de la Mata FJ, Pérez-Serrano J. 2013. In vitro comparative assessment of different viability assays in Acanthamoeba castellanii and Acanthamoeba polyphaga trophozoites. Parasitol. Res. 112:4087-4095. http://dx.doi.org/10.1007/s00436-013-3599-5.
59. Manning L, Laman M, Page-Sharp M, Salman S, Hwaiwhanje I, Morep N, Siba P, Mueller I, Karunajeewa HA, Davis TM. 2011. Meningeal inflammation increases artemether concentrations in cerebrospinal fluid in Papua New Guinean children treated with intramuscular artemether. Antimicrob. Agents Chemother. 55:5027-5033. http://dx.doi.org/10.1128/AAC.00375-11.
60. Morris CA, Duparc S, Borghini-Fuhrer I, Jung D, Shin CS, Fleckenstein L. 2011. Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. Malar. J. 10:263. http://dx.doi.org/10.1186/1475-2875-10-263.
61. Li Q, Cantilena LR, Leary KJ, Saviolakis GA, Miller RS, Melendez V, Weina PJ. 2009. Pharmacokinetic profiles of artesunate after single intravenous doses at 0.5, 1, 2, 4, and 8 mg/kg in healthy volunteers: a phase I study. Am. J. Trop. Med. Hyg. 81:615-621. http://dx.doi.org/10.4269/ajtmh.2009.09-0150.
62. Miller RS, Li Q, Cantilena LR, Leary KJ, Saviolakis GA, Melendez V, Smith B, Weina PJ. 2012. Pharmacokinetic profiles of artesunate following multiple intravenous doses of 2, 4, and 8 mg/kg in healthy volunteers: phase 1b study. Malar. J. 11:255. http://dx.doi.org/10.1186/1475-2875-11-255.
63. Davis TM, Binh TQ, Ilett KF, Batty KT, Phuöng HL, Chiswell GM, Phuong VDB, Agus C. 2003. Penetration of dihydroartemisinin into cerebrospinal fluid after administration of intravenous artesunate in severe falciparum malaria. Antimicrob. Agents Chemother. 47:368-370. http://dx.doi.org/10.1128/AAC.47.1.368-370.2003.
64. Kearney BP, Aweeka FT. 1999. The penetration of anti-infectives into the central nervous system. Neurol. Clin. 17:883-900. http://dx.doi.org/10.1016/S0733-8619(05)70171-7.
65. Schnepf N, Corvo J, Pors MJ, Mazeron MC. 2011. Antiviral activity of ganciclovir and artesunate towards human cytomegalovirus in astrocytoma cells. Antiviral Res. 89:186-188. http://dx.doi.org/10.1016/j .antiviral.2010.12.002.
66. Bethell D, Se Y, Lon C, Tyner S, Saunders D, Sriwichai S, Darapiseth S, Teja-Isavadharm P, Khemawoot P, Schaecher K, Ruttvisutinunt W, Lin J, Kuntawungin W, Gosi P, Timmermans A, Smith B, Socheat D, Fukuda MM. 2011. Artesunate dose escalation for the treatment of uncomplicated malaria in a region of reported artemisinin resistance: a randomized clinical trial. PLoS One 6:e19283. http://dx.doi.org/10.1371/journal.pone.0019283.